Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Idiopathic Pulmonary Fibrosis
NCT00063869Phase 2Completed
- Sponsor
- Pfizer
- Primary completion
- Mar 2005
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Etanercept with Placebo (2 arms). Primary endpoints: Forced Vital Capacity at 48 weeks, Diffusing Capacity of the Lung for Carbon Monoxide at 48 weeks and 2 more. Status: completed.
02
Drugs
etanercept
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00063869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063869.